Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.

Shanu Modi,Fabrice Andre,Ian E. Krop,Cristina Saura,Toshinari Yamashita,Sung-Bae Kim,Kenji Tamura,Shuquan Chen,Fumitaka Suto,Yusuke Kuwahara,Caleb Lee,Yeon Hee Park

Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.

2020

Shanu Modi
Fabrice Andre
Ian E. Krop
Cristina Saura
Toshinari Yamashita
Sung-Bae Kim
Kenji Tamura
Shuquan Chen
Fumitaka Suto
Yusuke Kuwahara
Caleb Lee
Yeon Hee Park

1036Background: Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable linker, and a cytotoxic topoisomerase I inhibitor. In the pivota...

Keywords:

Oncology
Trastuzumab
Subgroup analysis
Metastatic breast cancer
Pathology
Destiny
Internal medicine
Medicine
cleavable linker
Cytotoxic T cell
Conjugate
Cancer research
Topoisomerase-I Inhibitor
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations